Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.3: prohibited at all times. Non-Specified. [1]
S4.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Clinical research
Bimagrumab blocks activin type II receptors. In a 48-week randomized study of 75 adults with type 2 diabetes and overweight or obesity, treatment reduced fat mass and increased lean mass compared with placebo. Both groups also received diet and exercise counselling. Fifty-eight participants completed the study, and the main analysis focused on those completing treatment. [2]
- Disease-specific phase 2 study with attrition; it does not establish athlete performance benefit or routine treatment approval.
Safety and applicability
Diarrhea and muscle spasms were common in the bimagrumab group, and some participants discontinued because of adverse events. The study was too small and short to settle uncommon or long-term risks. [2]
- Do not translate changes in lean mass into a proven gain in strength or function.
What remains uncertain
- The cited 2026 Nature study was not retrievable. Its results and current approval status were not verified, and are not asserted here.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Bimagrumab versus placebo in adults with type 2 diabetes and obesity ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.